Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on February 11, 2015, covering events occurring on February 10 and 11, 2015. The company is a Delaware corporation headquartered in San Diego, CA.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses on corporate events rather than financial performance data.
Material Changes and Events
- Conference Presentation: CEO Antonius Schuh, Ph.D., is scheduled to present a corporate overview at the 2015 Leerink Global Healthcare Conference on February 12, 2015, in New York, NY.
- Capital Raise: The Company announced the closing of a previously announced underwritten public offering on February 11, 2015.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the standard disclosure of the offering closing and conference presentation.
Investor Verification Checklist
- Verify the final terms and total proceeds of the underwritten public offering closed on February 11, 2015 (refer to Exhibit 99.2).
- Review the press release regarding the Leerink Global Healthcare Conference presentation (refer to Exhibit 99.1).
- Confirm the company name is Trovagene, Inc., as the input metadata referenced Cardiff Oncology, Inc.